Xinrui Medtech, a cardiovascular device maker based in Suzhou, has reportedly raised “tens of millions” of renminbi in a pre-Series A financing round. The round was led by HM Capital, with a contribution from Northern Lights Venture Capital. The proceeds will be used to support clinical studies, new product research and development, and talent recruitment.
Company Overview and Achievements
Founded in 2021, Xinrui Medtech is known for its polymer valve core materials, which have been previously verified by a third party. The performance of these materials is comparable to that of US firm Foldax’s LifePolymer, highlighting Xinrui Medtech’s commitment to innovation and quality in cardiovascular device manufacturing.
Significance of the Financing
This pre-Series A financing round provides Xinrui Medtech with the necessary resources to accelerate its development and expand its product offerings. By investing in clinical studies and R&D, the company aims to bring more effective and reliable cardiovascular solutions to market, enhancing patient outcomes and quality of life.-Fineline Info & Tech
